Prime Highlight
- Schreiner MediPharm expanded its Needle-Trap system to support 2.25 ml, 3 ml, and 5 ml syringes, addressing the rise of high-viscosity, large-volume injectable drugs.
- The redesigned system improves safety, reduces production costs, and lowers carbon emissions while remaining compatible with existing manufacturing lines.
Key Facts
- The updated Needle-Trap system underwent extensive internal testing to ensure smooth operation on standard labeling and dispensing equipment.
- Its compact design allows easier storage, transport, and eco-friendly disposal across the pharmaceutical supply chain.
Background
Schreiner MediPharm has expanded its Needle-Trap needle protection system to support larger syringes, as drug makers increasingly use high-viscosity medicines that need higher fill volumes.
The company said the updated Needle-Trap system now works with 2.25 ml, 3 ml, and 5 ml syringes. Many new active pharma ingredients come with larger molecular structures and thicker formulations. These drugs need syringes that hold more liquid, which also raises the risk of needlestick injuries during production and use.
To meet this challenge, Schreiner MediPharm redesigned key elements of the Needle-Trap system. The company changed the design and how it works to maintain high safety, even for large-volume syringes. It also carried out extensive internal tests to ensure smooth processing at its own facilities and on standard labeling equipment used by pharmaceutical manufacturers.
The company said the solution offers a safer option compared with conventional needle guards and bulky autoinjector systems. Its compact design lets drug makers use less material, which lowers production costs and cuts carbon emissions.
Another big advantage is easy integration. Manufacturers don’t need new machines or to change their packaging process. The system works on standard dispensing lines, and secondary packaging stays the same. This saves companies time and prevents disruption to their existing setup.
Schreiner MediPharm also pointed out benefits for the whole supply chain. The smaller, lighter design takes up less space for storage, transport, and cooling. It also lets users dispose of the product in an eco-friendly way when it’s no longer needed.
The company aims to support the pharma industry as it moves toward more complex and higher-volume injectable drugs, while keeping safety, cost control and sustainability in focus.
